" "Oxford Immunotec Global PLC (NASDAQ:OXFD) Given Consensus Recommendation of " by Analysts

Elias Hubbard
August 3, 2017

Analyst's ratings play a very important role in outlining a stock's performance.

Oxford Immunotec Global PLC (OXFD) stock is interesting player of Wall Street Market in Tuesday trading session.

Several equities research analysts recently issued reports on the company. Zacks Investment Research cut Oxford Immunotec Global PLC from a "buy" rating to a "hold" rating in a report on Wednesday, May 3rd. Finally, ValuEngine raised shares of Oxford Immunotec Global PLC from a "sell" rating to a "hold" rating in a report on Friday, June 2nd. Axa stated it has 0.04% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD).

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and global copyright & trademark legislation.

Among 9 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 2 have Buy rating, 1 Sell and 6 Hold. Denver Investment Limited Liability Company holds 0.01% or 20,931 shares in its portfolio. It indicates oversold and overbought price levels for a stock. Following the completion of the transaction, the insider now directly owns 149,544 shares of the company's stock, valued at approximately $2,114,552.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Schroeder Jeff R. sold $565,659 worth of stock or 40,000 shares. EHRLICH DONALD J had sold 10,578 shares worth $888,340 on Tuesday, February 14. The Envestnet Asset Management Inc holds 2,115 shares with $109,000 value, down from 9,179 last quarter. The disclosure for this sale can be found here. The insider now directly owns 25,393 shares worth $490,339.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Finally, TFS Capital LLC raised its stake in Oxford Immunotec Global PLC by 19.8% in the first quarter. Neuberger Berman Group LLC now owns 134,229 shares of the company's stock worth $2,079,000 after buying an additional 79,129 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Oxford Immunotec Global PLC by 175.0% in the first quarter. American International Group Inc. now owns 13,668 shares of the company's stock worth $212,000 after buying an additional 904 shares during the period. TFS Capital LLC boosted its stake in shares of Oxford Immunotec Global PLC by 19.8% in the first quarter. Zebra Capital Management Llc owns 59,820 shares or 0.74% of their USA portfolio.

Oxford Immunotec Global PLC is a diagnostics company. Essex Investment Management Co. First Light Asset Ltd Com has invested 4.91% in Oxford Immunotec Global PLC (NASDAQ:OXFD).

Let's take an assessment at how Oxford Immunotec Global PLC (OXFD) has been performing. Retail Bank Of New York Mellon Corp accumulated 70,306 shares or 0% of the stock. Endurant Capital Management L P invested 0.1% in Oxford Immunotec Global PLC (NASDAQ:OXFD). The corporation has a market cap of US$450.5 Million. The corporation has a 50 Day SMA price of $15.98 and a two hundred SMA of $14.87.

Oxford Immunotec Global PLC (NASDAQ:OXFD)'s earnings per share has been growing at a -4.5 percent rate over the past 5 year when average revenue increase was noted as 46.8 percent. New Leaf Venture Prtn Ltd Company owns 14.75% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 1.38M shares. The company's quarterly revenue was up 35.9% on a year-over-year basis. Moreover, Stanley has 0.36% invested in the company for 28,249 shares.

According to Zacks, analysts expect that Oxford Immunotec Global PLC will report full-year sales of $25.30 million for the current fiscal year, with estimates ranging from $103.39 million to $104.88 million. The corporation is focused on developing and commercializing tests for under-served immune-regulated conditions. the firms product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Other reports by Click Lancashire

Discuss This Article